Clinicopathological and Biological Significance of Aberrant Activation of Glycogen Synthase Kinase-3 in Ovarian Cancer

OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s62158
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Role of Glycogen Synthase Kinase-3β Inhibitor AZD1080 in Ovarian Cancer

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2016English

Glycogen Synthase Kinase-3

International Journal of Alzheimer's Disease
AgingCognitive NeuroscienceMolecular NeuroscienceNeurologyBehavioral NeuroscienceCellular
2011English

Aberrant Expression of Glycogen Synthase Kinase‑3β in Human Breast and Head and Neck Cancer

Oncology Letters
Cancer ResearchOncology
2018English

Aberrant Expression of ADAM9 in Ovarian Cancer and Its Clinical Significance

Journal of Clinical Laboratory Analysis
AllergyImmunologyBiochemistryPublic HealthMedical Laboratory TechnologyClinical BiochemistryHematologyMicrobiologyEnvironmentalOccupational Health
2019English

Glycogen Synthase Kinase-3 in Neurodegeneration and Neuroprotection:Lessons From Lithium

Current Alzheimer Research
Neurology
2007English

Erratum To: Activation of Glycogen Synthase Kinase-3 Mediates the Olfactory Deficit-Induced Hippocampal Impairments

Molecular Neurobiology
NeuroscienceNeurologyCellularMolecular Neuroscience
2015English

Glycogen Synthase Kinase 3 in MLL Leukaemia Maintenance and Targeted Therapy

Nature
Multidisciplinary
2008English

Glycogen Synthase Kinase-3 Is a Negative Regulator of Extracellular Signal-Regulated Kinase

Oncogene
Cancer ResearchGeneticsMolecular Biology
2005English

Computer-Aided Molecular Design of Pyrazolotriazines Targeting Glycogen Synthase Kinase 3

Journal of Enzyme Inhibition and Medicinal Chemistry
MedicineDrug DiscoveryPharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy